Relates to medical use of psilocybin; establishes a psilocybin assisted therapy grant program; makes an appropriation therefor.
S00495 would create a new framework in New York law for the medical use of psilocybin, a psychedelic compound found in certain mushrooms. The bill adds a new title to the Public Health Law establishing definitions, lawful medical use standards, facilitator certification requirements, department oversight, research and evaluation authority, patient and practitioner protections, a grant program, a naturally grown psilocybin pilot, and an advisory board to guide implementation. It also amends the State Finance Law to create a dedicated fund and appropriates $5 million to launch the program.
Under the bill, psilocybin could be used for certified medical purposes only in supervised clinical settings, including a facilitator’s office, hospital, or, for patients unable to travel, at home. The Department of Health would be responsible for regulations, facilitator training, program evaluation, and biennial reporting to the governor and legislature. The bill also contemplates research programs, public education, and coordination with federal law and agencies, while allowing facilitators to access future FDA-approved synthetic psilocybin or MDMA products if available.
The bill would amend the Public Health Law and State Finance Law to create a new regulated medical psilocybin program and a new state fund for psilocybin and MDMA-assisted therapy grants. It would provide legal protections for patients, practitioners, and facilitators acting under the title, exempt certain records from public disclosure, and direct state agencies to develop rules for cultivation, treatment, and oversight. It would also establish a pilot for in-state cultivation of naturally grown psilocybin mushrooms and authorize grants for veterans, first responders, retired first responders, and low-income individuals.
The bill appears generally supportive of expanding access to psilocybin-assisted therapy, with a strong public-health and treatment-oriented framing. Its structure emphasizes regulated access, research, safety standards, and targeted financial assistance for populations often highlighted in mental health and trauma treatment discussions. No committee transcripts or recorded votes were provided, so there is no documented formal debate or vote-based sentiment to assess beyond the bill’s text and sponsors’ apparent policy direction.
The main points of potential contention are likely to be the legalization of psilocybin for medical use, the creation of a state-funded program, and the cultivation of psilocybin mushrooms in New York. The bill also raises federal-law concerns by explicitly acknowledging that no person or entity is required to violate federal law or risk federal funding, suggesting anticipated conflict over controlled-substances rules. Additional areas of debate may include the scope of patient access, home treatment, public disclosure of facilitator information, and whether the state should invest in psilocybin and MDMA-assisted therapy before broader federal approval.